Abstract
Antibacterial resistance is an alarming global concern and a public health challenge of the twenty-first century for which effective systems are required to track and treat ABR. We performed microbiological and antibiotic susceptibility testing on the samples to detect and characterize Multidrug-Resistant Bacteria (MDRB) isolated from patients segregating MDRB characteristics (types, prevalence and distribution of MDRB) based on time (i.e., during versus post covid-19) and location (i.e., different wards of a tertiary care hospital). We observed an increase of MDRB in 2022 as compared to 2021 and 2023. These MDRB had a Shannon and Simpson index values of 1.138 to 1.508 and 0.643 to 0.775, respectively and an observed evenness values of 0.780 to 1.042, which revealed the microbial diversity recovered from the patient samples. In keeping with previous MDR studies, Klebsiella, E. coli, Citrobacter, Acinetobacter and Pseudomonas were identified from the patient samples. Moreover, compared to previous reports, the percentage of MDR-bacteria, i.e., Klebsiella (40 %), E. coli (28 %), and Citrobacter (19 %), populations were higher in this study. We observed that Gamma-proteobacteria were predominant across all the recovered samples, and that Acinetobacter and Klebsiella isolated from the samples were 100 % resistant to twenty and eleven antibiotics, respectively. Furthermore, the fatality rate was low compared with the available reports suggesting possibilities for effective recovery if given rapid and tailored treatment. Given the challenges faced by MDRB strains more surveillance and tracking is needed to ensure effective and specifically targeted treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Symbiosis International (Deemed University), [(Established under section 3 of the UGC Act 1956),Pune, Maharashtra, India], IEC ethics committee has approved this study (dated 31 December 2022). Waiver of consent is granted for the study. Reference No. SIU/IEC/477
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
